Showing 3311-3320 of 7015 results for "".
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
https://reachmd.com/programs/project-oncology/car-t-and-bispecifics-in-lbcl-redefining-second-line-therapy-choices/35457/This is a non-certified educational series produced and controlled by ReachMD. The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only forThe Skin and the Pursuit of Beauty
https://reachmd.com/topics/skincare/the-skin-and-the-pursuit-of-beauty/36685/With Steven H. Dayan, MD, FACSMenin Inhibitors: Biologic and Clinical Rationale
https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.COVID-19 Recovery: Investigating the Link Between Inflammation and Cognitive Symptoms
https://reachmd.com/programs/clinicians-roundtable/covid-19-recovery-investigating-the-link-between-inflammation-and-cognitive-symptoms/35465/A post hoc analysis of the CONTAIN randomized clinical trial tracked inflammatory markers and health outcomes up to 18 months post-hospitalization. Based on the results, markers like cytokines, D-dimer, and fibrinogen declined over time, and no clear link was found between persistent inflammation anEvolving Strategies in Limited-Stage Small Cell Lung Cancer Management
https://reachmd.com/programs/deep-breaths-updates-chest/evolving-strategies-in-limited-stage-small-cell-lung-cancer-management/32963/Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timelyEnhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
https://reachmd.com/programs/cme/enhancing-diagnosis-treatment-and-outcomes-in-paroxysmal-nocturnal-hemoglobinuria-with-novel-oral-therapeutics/32762/Join Dr. Carlos de Castro and learn about best practices for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria.Optimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
https://reachmd.com/programs/frontlines-schizophrenia/optimizing-schizophrenia-care-strategies-for-managing-side-effects-and-treatment-resistance/30035/Learn about strategies for managing common therapeutic challenges in schizophrenia.Reducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
https://reachmd.com/programs/neurofrontiers/reducing-cortical-lesions-in-ms-with-ocrelizumab-results-from-the-oratori-study/26763/Does the B-cell therapy ocrelizumab have the potential to slow down cortical lesions or even stop them in multiple sclerosis (MS)? That’s the exact question the ORATORI study sought to answer, and based on the findings, not only did ocrelizumab reduce new and enlarging cortical lesions by 75 percentNavigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
https://reachmd.com/programs/project-oncology/navigating-mcrpc-treatment-a-look-at-abiraterone-and-enzalutamide/28644/Explore the efficacy of abiraterone and enzalutamide in treating metastatic castration-resistant prostate cancer.The BALTAZAR Study: How Caffeine Intake Affects Alzheimer's Biomarkers
https://reachmd.com/programs/neurofrontiers/the-baltazar-study-how-caffeine-intake-affects-alzheimers-biomarkers/29092/Here’s how daily caffeine intake could benefit cognitive functioning, particularly in patients with Alzheimer’s disease or mild cognitive impairment.